Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 307

Next Previous
Drug Profile

CB 307

Alternative Names: CB-307

Latest Information Update: 10 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crescendo Biologics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD137 antigen agonists; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Sep 2024 CB 307 is still in phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in United Kingdom, Spain, Netherlands, and USA (IV) (NCT04839991) (EudraCT2019-004584-46)
  • 14 Sep 2024 Pharmacokinetics data from a phase I POTENTIA trial in Solid tumours released by Crescendo Biologics
  • 13 Sep 2024 Pharmacokinetics data from a substudy of phase I trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top